Jeremy Bray was emotional upon learning that the Manitoba government had not granted his request for coverage of his essential treatment despite his efforts. Bray, a 30-year-old with a degenerative disease affecting his muscle movement, met with Health Minister Uzoma Asagwara following his appeal to the NDP administration to fund his medication to maintain his independence. He currently has limited muscle control, only able to move parts of his face and one thumb.
Expressing his disappointment to reporters after the meeting, Bray emphasized his desire for his home province to support his treatment with the drug risdiplam, marketed as Evrysdi, which has shown positive results in his case over the past six months. Asagwara had previously negotiated with Roche, the drug manufacturer, for complimentary coverage based on compassionate grounds.
Despite Bray’s notable improvements, including a stronger voice and increased work hours, the Canadian Drug Agency (CDA) has hesitated to recommend the treatment for adults over 25, citing insufficient data from clinical trials involving this age group. Bray’s hope for continued access to the drug was dashed when Roche announced the end of free coverage, prompting him to seek intervention from the provincial government.
While Bray and his family remained optimistic about a policy reversal, the province upheld its decision not to intervene in the CDA’s guidance. Disheartened by the outcome, Bray’s father implied financial concerns as a potential reason for Manitoba’s stance, given the substantial cost of the treatment. The provincial government’s reluctance was criticized by opposition leader Obby Khan, who condemned the decision as callous and heartless.
Dr. Xavier Rodrigue, a Quebec physician specializing in spinal muscular atrophy, dismissed the need for further studies to validate the drug’s efficacy, citing existing evidence of its benefits. Asagwara reiterated the government’s commitment to advocating for Bray’s case and urged collaboration between Roche and the CDA to reconsider their position based on Bray’s real-world treatment experience.
Following the setback, Bray and his family affirmed their determination to explore alternative funding options for his ongoing treatment, emphasizing their unwavering support despite the province’s decision.